Craig C. Reed

Craig C. Reed

Auto-generated profile, based on publicly available information

Craig C. Reed

Center for Esophageal Diseases and Swallowing

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 January 2018 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
CRCraig C. Reed
Craig C. Reed
ASAnca M. Safta
Anca M. Safta
SQShadi Qasem
Shadi Qasem
MAM. Angie Almond
M. Angie Almond
EDEvan S. Dellon
Evan S. Dellon
EJElizabeth T. Jensen
Elizabeth T. Jensen

16 May 2024 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
CKCorey J. Ketchem
Corey J. Ketchem
CRCraig C. Reed
Craig C. Reed
EDEvan S. Dellon
Evan S. Dellon
INTRODUCTION: It is unknown whether concomitant esophageal involvement or anatomic location of eosinophilic infiltration affects the natural history of eosinophilic gastrointestinal disease (EGID). METHODS: A retrospective cohort study was performed using the University of North Carolina EGID Clinicopathologic Database. Patients were adults and children with a prior EGID diagnosis based on clinicopathologic features. Demographics, clinical characteristics, treatment information, and procedural data were extracted from medical records. Clinical course and flare history were characterized. RESULTS: Among 97 patients, 43% had EGID + esophageal involvement and 57% had EGID only. Patients with esophageal involvement had a longer diagnostic delay preceding diagnosis (36.6 vs 11.6 months, P = 0.001), more dysphagia (50% vs 18%; P = 0.001), required more chronic therapy (77% vs 52%, P = 0.016), and exhibited more progressive disease (25% vs 6%, P = 0.027). A continuous disease course was most common in eosinophilic gastritis (78%) while patients with eosinophilic gastritis + eosinophilic enteritis (29%) and eosinophilic enteritis + eosinophilic colitis (50%) had the highest proportion of progressive and relapsing disease, respectively (P = 0.045). A continuous disease course occurred more frequently in children (71%, P = 0.03) and those with single organ involvement (65%), whereas adults had more relapsing (39%) or progressive disease (18%). DISCUSSION: EGIDs with and without esophageal involvement display many similarities, although patients with esophageal involvement more frequently had dysphagia, had progressive disease courses, and required more chronic therapy. Location of involvement and age of onset affected the natural history with higher proportions of relapsing or progressive disease seen in adults and patients with small bowel or multiorgan involvement while a continuous disease course was more common in children and patients with gastric-only involvement.

25 October 2023 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
AKAkshatha Kiran
Akshatha Kiran
EDEvan S. Dellon
Evan S. Dellon
CRCraig C. Reed
Craig C. Reed

9 December 2025 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
CRCraig C. Reed
Craig C. Reed
SAStefani Aleman
Stefani Aleman
AWAlexandra A. Weir
Alexandra A. Weir
SLSean S. LaFata
Sean S. LaFata
TGTimothy S. Gee
Timothy S. Gee
EDEvan S. Dellon
Evan S. Dellon
INTRODUCTION: Assessment of eosinophilic esophagitis (EoE) endoscopic findings is critical in determining disease activity. However, response thresholds for the EoE Endoscopy Reference Score (EREFS) are not definitively established. We assessed EREFS response thresholds in patients with EoE treated with topical corticosteroids. METHODS: We conducted a retrospective cohort study of newly diagnosed patients with EoE treated with topical corticosteroid who had a follow-up endoscopy with biopsy and EREFS assessed pretreatment/post-treatment. We explored endoscopic response thresholds. Patients with and without endoscopic response were compared and predictors of response were determined. Histologic and global symptom responses were determined and residual endoscopic findings calculated. RESULTS: Of 333 patients, 219 (68%), 206 (62%), 142 (43%), 70 (21%), 139 (42%), and 142 (43%) met response thresholds for EREFS ≤2, EREFS ≤2 with no components >1 nor worsening of any component, EREFS ≤1, EREFS = 0, inflammatory subscore = 0, and fibrostenotic subscore = 0, respectively. On multivariate analysis, lower body mass index (adjusted odds ratio [aOR]: 0.90; 95% confidence interval [CI]: 0.85–0.95), heartburn (aOR: 2.74; 95% CI: 1.37–5.48), and lower total baseline EREFS (aOR: 0.57; 95% CI: 0.29–0.71) independently predicted EREFS ≤2. After treatment, 74% with EREFS≤2 vs 23% with EREFS>2 ( P < 0.001) had histologic response at <15 eos/hpf. Endoscopic responders more frequently endorsed a global symptom response (89% vs 56%; P < 0.001) and had minimal residual endoscopic findings. Outcomes stratified for adults and children were comparable with the entire cohort. DISCUSSION: Post-treatment EREFS ≤2 was consistent with symptom and histologic response for the entire cohort. These data support EREFS ≤2 as a robust threshold to define endoscopic response.

25 October 2017 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
BJBiljana Jovov
Biljana Jovov
CRCraig C. Reed
Craig C. Reed
NSNicholas J. Shaheen
Nicholas J. Shaheen
APAmy Pruitt
Amy Pruitt
KFKathleen Ferrell
Kathleen Ferrell
RORoy C. Orlando
Roy C. Orlando

18 April 2018 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
CRCraig C. Reed
Craig C. Reed
NSNicholas J. Shaheen
Nicholas J. Shaheen